Relationship between HuR and tumor drug resistance
Qiancheng Ma1, Qiliang Lu2, Xiangxiang Lei3
1College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, 310014, China.
Summary
Human resistance protein R (HuR) drives cancer drug resistance by affecting mRNA stability. Targeting HuR offers a potential therapeutic strategy and prognostic marker for various human cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Human resistance protein R (HuR), also known as ELAVL1, is an RNA-binding protein.
- HuR regulates mRNA stability and is crucial for post-transcriptional gene regulation.
- Aberrant HuR expression is linked to poor prognosis in various human cancers.
Purpose of the Study:
- To review the role of HuR in cancer drug resistance.
- To explore HuR as a potential therapeutic target and prognostic marker.
- To summarize HuR's mechanisms of tumor resistance and affected molecular targets.
Main Methods:
- Literature review of studies on HuR and cancer drug resistance.
- Analysis of HuR's structure, function, and inhibitors.
- Summary of mechanisms underlying HuR-mediated tumor resistance.
Main Results:
- HuR plays a significant role in the development of drug resistance across multiple tumor types.
- HuR influences the stability of mRNAs encoding proteins involved in drug resistance.
- Inhibitors of HuR are being investigated for their therapeutic potential.
Conclusions:
- HuR is a critical factor in cancer progression and drug resistance.
- Targeting HuR presents a promising avenue for novel cancer therapies.
- HuR can serve as a valuable biomarker for treatment efficacy and patient prognosis.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.3K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.7K
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
01:12Hazard Ratio
187
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
187